| Aktie | Ticker | Breite | GCS | 2026/Q2 | 2026/Q1 | 2025/Q4 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| 398.034.838 $ | +88.449.946 $ | +34,1 % | 35 | 352.219.185 $ | +26.928.001 $ | +27,4 % | 34 | 338.852.146 $ | +338.852.146 $ | 34 | |||||
| Cogent Biosciences, Inc. | COGT | → 0 | Neutral | 45.307.638 $ | +245.855 $ | +0,5 % | 1 | 45.061.783 $ | +3.477.098 $ | +8,4 % | 1 | 41.584.685 $ | +41.584.685 $ | 1 | |
| Syndax Pharmaceuticals Inc | SNDX | → 0 | Schwach | 40.550.300 $ | -2.782.500 $ | -6,4 % | 1 | 43.332.800 $ | +4.359.250 $ | +11,2 % | 1 | 38.973.550 $ | +38.973.550 $ | 1 | |
| Celldex Therapeutics, Inc. | CLDX | → 0 | Neutral | 36.837.900 $ | +9.400.100 $ | +34,3 % | 1 | 27.437.800 $ | +3.944.400 $ | +16,8 % | 1 | 23.493.400 $ | +23.493.400 $ | 1 | |
| Relay Therapeutics, Inc. | RLAY | → 0 | Neutral | 27.415.370 $ | +22.072.757 $ | +413,1 % | 1 | 5.342.613 $ | +800.050 $ | +17,6 % | 1 | 4.542.563 $ | +4.542.563 $ | 1 | |
| Viridian Therapeutics, Inc.\DE | VRDN | → 0 | Neutral | 18.093.182 $ | +7.629.932 $ | +72,9 % | 1 | 10.463.250 $ | -16.257.347 $ | -60,8 % | 1 | 26.720.597 $ | +26.720.597 $ | 1 | |
| Vaxcyte, Inc. | PCVX | → 0 | Neutral | 26.294.524 $ | +7.902.709 $ | +43,0 % | 1 | 18.391.815 $ | +4.942.005 $ | +36,7 % | 1 | 13.449.810 $ | +13.449.810 $ | 1 | |
| Vera Therapeutics, Inc. | VERA | → 0 | Schwach | 18.730.987 $ | -679.988 $ | -3,5 % | 1 | 19.410.975 $ | -5.022.825 $ | -20,6 % | 1 | 24.433.800 $ | +24.433.800 $ | 1 | |
| CytomX Therapeutics, Inc. | CTMX | → 0 | Stark | 17.062.500 $ | -4.322.500 $ | -20,2 % | 1 | 21.385.000 $ | +18.403.000 $ | +617,1 % | 1 | 2.982.000 $ | +2.982.000 $ | 1 | |
| KalVista Pharmaceuticals, Inc. | KALV | → 0 | 20.558.769 $ | +7.617.774 $ | +58,9 % | 1 | 12.940.995 $ | +12.940.995 $ | 1 | ||||||
| CG Oncology, Inc. | CGON | → 0 | Schwach | 19.749.024 $ | -699.576 $ | -3,4 % | 1 | 20.448.600 $ | +20.448.600 $ | 1 | |||||
| Pharvaris N.V. | PHVS | → 0 | Stark | 18.180.435 $ | +4.740.497 $ | +35,3 % | 1 | 13.439.938 $ | +237.875 $ | +1,8 % | 1 | 13.202.063 $ | +13.202.063 $ | 1 | |
| BIOCRYST PHARMACEUTICALS INC | BCRX | → 0 | Stark | 5.200.000 $ | -4.320.000 $ | -45,4 % | 1 | 9.520.000 $ | -7.250.000 $ | -43,2 % | 1 | 16.770.000 $ | +16.770.000 $ | 1 | |
| Travere Therapeutics, Inc. | TVTX | → 0 | Neutral | 16.622.606 $ | +11.346.110 $ | +215,0 % | 1 | 5.276.496 $ | +1.073.396 $ | +25,5 % | 1 | 4.203.100 $ | +4.203.100 $ | 1 | |
| Legend Biotech Corp | LEGN | → 0 | Neutral | 16.478.033 $ | +16.478.033 $ | 1 | |||||||||
| Beam Therapeutics Inc. | BEAM | → 0 | Schwach | 16.347.920 $ | +4.996.785 $ | +44,0 % | 1 | 11.351.135 $ | -1.852.954 $ | -14,0 % | 1 | 13.204.089 $ | +13.204.089 $ | 1 | |
| Tyra Biosciences, Inc. | TYRA | → 0 | Schwach | 638.800 $ | -12.766.200 $ | -95,2 % | 1 | 13.405.000 $ | +4.203.500 $ | +45,7 % | 1 | 9.201.500 $ | +9.201.500 $ | 1 | |
| Cullinan Therapeutics, Inc. | CGEM | → 0 | Neutral | 12.564.900 $ | +5.033.600 $ | +66,8 % | 1 | 7.531.300 $ | +4.322.800 $ | +134,7 % | 1 | 3.208.500 $ | +3.208.500 $ | 1 | |
| Nurix Therapeutics, Inc. | NRIX | → 0 | Neutral | 11.159.600 $ | +4.029.600 $ | +56,5 % | 1 | 7.130.000 $ | -1.596.200 $ | -18,3 % | 1 | 8.726.200 $ | +8.726.200 $ | 1 | |
| DYNAVAX TECHNOLOGIES CORP | DVAX | → 0 | 10.456.862 $ | +10.456.862 $ | 1 | ||||||||||
| UNITED THERAPEUTICS Corp | UTHR | → 0 | Stark | 8.127.450 $ | -767.250 $ | -8,6 % | 1 | 8.894.700 $ | +3.534.950 $ | +66,0 % | 1 | 5.359.750 $ | +5.359.750 $ | 1 | |
| Krystal Biotech, Inc. | KRYS | → 0 | Neutral | 8.176.740 $ | +2.493.700 $ | +43,9 % | 1 | 5.683.040 $ | +259.160 $ | +4,8 % | 1 | 5.423.880 $ | +5.423.880 $ | 1 | |
| Wave Life Sciences, Inc. | WVE | → 0 | 1.033.285 $ | -256.099 $ | -19,9 % | 1 | 1.289.384 $ | -6.323.998 $ | -83,1 % | 1 | 7.613.382 $ | +7.613.382 $ | 1 | ||
| Summit Therapeutics Inc. | SMMT | → 0 | Neutral | 7.194.957 $ | +7.194.957 $ | 1 | |||||||||
| INSMED Inc | INSM | → 0 | Neutral | 6.930.300 $ | +6.930.300 $ | 1 | |||||||||
| MBX Biosciences, Inc. | MBX | → 0 | Schwach | 5.023.200 $ | -1.275.150 $ | -20,2 % | 1 | 6.298.350 $ | -356.590 $ | -5,4 % | 1 | 6.654.940 $ | +6.654.940 $ | 1 | |
| DBV Technologies S.A. | DBVT | → 0 | Neutral | 4.346.000 $ | -1.189.850 $ | -21,5 % | 1 | 5.535.850 $ | +5.535.850 $ | 1 | |||||
| BIOMARIN PHARMACEUTICAL INC | BMRN | → 0 | Neutral | 2.689.340 $ | +34.310 $ | +1,3 % | 1 | 2.655.030 $ | -2.218.230 $ | -45,5 % | 1 | 4.873.260 $ | +4.873.260 $ | 1 | |
| Protagonist Therapeutics, Inc | PTGX | → 0 | Neutral | 4.658.040 $ | +652.840 $ | +16,3 % | 1 | 4.005.200 $ | +686.280 $ | +20,7 % | 1 | 3.318.920 $ | +3.318.920 $ | 1 | |
| UroGen Pharma Ltd. | URGN | → 0 | Schwach | 4.416.000 $ | +460.400 $ | +11,6 % | 1 | 3.955.600 $ | +1.613.600 $ | +68,9 % | 1 | 2.342.000 $ | +2.342.000 $ | 1 | |
| ALUMIS INC. | ALMS | → 0 | Neutral | 3.658.200 $ | +794.300 $ | +27,7 % | 1 | 2.863.900 $ | +2.863.900 $ | 1 | |||||
| SUPERNUS PHARMACEUTICALS, INC. | SUPN | → 0 | Stark | 3.255.700 $ | +2.221.900 $ | +214,9 % | 1 | 1.033.800 $ | +39.800 $ | +4,0 % | 1 | 994.000 $ | +994.000 $ | 1 | |
| Liquidia Corp | LQDA | → 0 | Schwach | 3.104.100 $ | +3.104.100 $ | 1 | |||||||||
| Immunocore Holdings plc | IMCR | → 0 | Neutral | 2.576.290 $ | +820.113 $ | +46,7 % | 1 | 1.756.177 $ | -265.611 $ | -13,1 % | 1 | 2.021.788 $ | +2.021.788 $ | 1 | |
| Design Therapeutics, Inc. | DSGN | → 0 | Schwach | 1.561.313 $ | -650.743 $ | -29,4 % | 1 | 2.212.056 $ | +261.954 $ | +13,4 % | 1 | 1.950.102 $ | +1.950.102 $ | 1 | |
| Amylyx Pharmaceuticals, Inc. | AMLX | → 0 | Neutral | 2.011.520 $ | +454.720 $ | +29,2 % | 1 | 1.556.800 $ | +203.840 $ | +15,1 % | 1 | 1.352.960 $ | +1.352.960 $ | 1 | |
| Apellis Pharmaceuticals, Inc. | APLS | → 0 | 2.011.500 $ | +755.500 $ | +60,2 % | 1 | 1.256.000 $ | +1.256.000 $ | 1 | ||||||
| Alector, Inc. | ALEC | → 0 | Neutral | 1.809.000 $ | -126.000 $ | -6,5 % | 1 | 1.935.000 $ | +531.000 $ | +37,8 % | 1 | 1.404.000 $ | +1.404.000 $ | 1 | |
| enGene Therapeutics Inc. | ENGN | → 0 | Neutral | 363.300 $ | -1.066.800 $ | -74,6 % | 1 | 1.430.100 $ | -466.200 $ | -24,6 % | 1 | 1.896.300 $ | +1.896.300 $ | 1 | |
| Septerna, Inc. | SEPN | → 0 | Neutral | 1.655.880 $ | +1.655.880 $ | 1 | |||||||||
| SUTRO BIOPHARMA, INC. | STRO | → 0 | Schwach | 1.063.628 $ | +1.063.628 $ | 1 | |||||||||
| Edgewise Therapeutics, Inc. | EWTX | → 0 | Neutral | 315.000 $ | -429.450 $ | -57,7 % | 1 | 744.450 $ | +744.450 $ | 1 | |||||
| 398.034.838 $ | +88.449.946 $ | +34,1 % | 35 | 352.219.185 $ | +26.928.001 $ | +27,4 % | 34 | 338.852.146 $ | +338.852.146 $ | 34 | |||||